Navigation Links
The Leukemia & Lymphoma Society: Impacting Blood Cancers and Beyond
Date:2/19/2013

s as soon as possible. LLS works in concert with academic investigators, medical centers and pharmaceutical and biotechnology companies to move promising therapies quickly from the laboratory into clinical trials and, ultimately, to patients.

LLS continues to support and fund the world's best and brightest academic scientists and award grants based on merit to advance progress in all areas of blood cancer research, and at all stages from basic science to clinical trials. Through our grants programs we support the development of the next generation of first rate cancer researchers.

Proof of LLS's cure-focused, patient-centered infrastructure is apparent from the allocation of its funds. Last year, 78 percent of the money spent by LLS went to research, patient and community services, advocacy and education. Its co-pay assistance program provided $44.2 million to almost 14,000 patients in need. LLS's Office of Public Policy team advocates for policies that help speed the approval process for new blood cancer therapies and ensure access to quality, affordable and coordinated care for patients.

"Ultimately, cancer affects everyone," said Walter. "We all have an opportunity to impact a cure for this disease now. Someday truly is today."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Key LLS fundraising campaigns include Team In Training, Light The Night, School & Youth, Man & Woman of the Year and Regatta. To reach the widest possible audience, LLS partners with national and regional level companies and brands, including Nike, Disney, Burlington
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
2. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
3. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
4. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
5. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
6. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
7. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
8. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
9. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
10. Founder of National Childrens Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe
11. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... (Nasdaq: ARNA ) today announced it will report ... closes on Monday, May 11, 2009. That same afternoon, Jack ... Hoffman, Arena,s Vice President, Finance and Chief Financial Officer, will ... p.m. Pacific Time) to discuss the financial results for the ...
... On Thursday, May 7, 2009, at 8:30 a.m. Eastern/2:30 p.m. Central ... CTIC) management team will host a conference call to discuss the Company,s ... Conference Call Numbers, ... 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time, ...
... Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or ... three-month period ended March 31, 2009. , "The first ... very positive results in several of our combination REOLYSIN(R) ... of Oncolytics. "We continue to report clinical benefit in ...
Cached Biology Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009 3Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7 2Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 2Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 3Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 4Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 5Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 6Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 7Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 8
(Date:4/22/2014)... Biotechnology scientists must be aware of the broad ... guidelines, according to a new paper from Rice University,s ... current issue of the journal Regenerative Medicine , ... Supreme Court ruling in the case Association for Molecular ... are unpatentable. The court case and rulings garnered discussion ...
(Date:4/22/2014)... Scientists at the University of Massachusetts Amherst and ... this week report that they have discovered a new ... of the Negro River in the Amazonia State of ... with Adlia Nogueira and Jos Antnio Alves-Gomes of INPA, ... of the journal Proceedings of the Natural Sciences ...
(Date:4/22/2014)... of nanotechnology researchers at the University of Kentucky has ... arrays using RNA. , The research, led by ... in Nanobiotechnology at the UK College of Pharmacy and ... "RNA as a Boiling-Resistant Anionic Polymer Material To Build ... Emil F. Khisamutdinov and Daniel L. Jasinski. , The ...
Breaking Biology News(10 mins):New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3New electric fish genus and species discovered in Brazil's Rio Negro 2RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2
... from the Department of Defense will allow North Carolina ... Institute of Research to further test the effectiveness of ... infections. The two-and-a-half-year project will show the efficacy ... and Dr. John Cavanagh against different types of animal ...
... McMaster University is establishing the first NVIDIA CUDA ... of only twelve worldwide, will teach electrical and ... processing resources available in graphics processing units (GPU) ... CUDA is a parallel computing architecture that enables ...
... antibacterial ingredient in some soaps, toothpastes, odor-fighting socks, and ... new treatment for a parasitic disease that affects almost ... the guiding light for future development of drugs for ... Chemistry . In the study, Rima McLeod and ...
Cached Biology News:NC State research grant will help military combat infections 2McMaster, NVIDIA establish first CUDA Teaching Centre in Canada 2
...
... maintenance, calibration, and validation (MCV) ... 96-well plate used for hands-free ... procedures using the Bio-Plex suspension ... is for use with Bio-Plex ...
...
... SureLINK HRP Conjugation Kits are based ... conjugates that are consistent and reproducible. ... to conjugate your protein or antibody, ... storage buffer. Activated HRP is ...
Biology Products: